Get the Stockscreener App
2.76
2.13%
-0.06
After Hours:
2.70
-0.06
-2.17%
Galmed Pharmaceuticals Ltd Stock (GLMD) Forecast
The Galmed Pharmaceuticals Ltd (GLMD) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $8.321, representing a +201.49% increase from the current price of $2.76. The highest analyst price target is $15.94, and the lowest is $0.6993.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month GLMD Price Target
Average 17.59
(+537.16% Upside)
Is Galmed Pharmaceuticals Ltd (GLMD) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 40.92 | Neutral |
| STOCH(9,6) | 25.69 | Neutral |
| STOCHRSI(14) | 4.1096 | Buy |
| MACD(12,26) | -0.0595 | Sell |
| ADX(14) | 21.55 | Neutral |
| William %R | -92.00 | Buy |
| CCI(14) | -60.19 | Neutral |
Buy: 2
Sell: 1
Neutral: 4
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
2.8781
Sell
|
2.8699
Sell
|
| MA20 |
2.9533
Sell
|
2.9158
Sell
|
| MA50 |
2.9436
Sell
|
3.0892
Sell
|
| MA100 |
3.835
Sell
|
3.4115
Sell
|
| MA200 |
3.922
Sell
|
3.8197
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, GLMD could be considered a Strong Sell, with 17 technical analysis indicators signaling 2 Buy signals, 11 signaling Sell signals and 4 Neutral signals. This might not be a good time to consider opening new positions on GLMD, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 40.92 indicates that GLMD is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 25.69 indicates that GLMD is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 4.1096 indicates that GLMD is oversold. This suggests that GLMD price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 21.55 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -60.19 indicates that GLMD is still oversold but not to an extreme extent.
Long-term GLMD price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Galmed Pharmaceuticals Ltd financial reports and earnings history, Galmed Pharmaceuticals Ltd (GLMD) stock could reach $111.91 by 2030, $64.07 by 2040 and $212.37 by 2050. See the projected annual prices until 2050 of the Galmed Pharmaceuticals Ltd stock below:
- Galmed Pharmaceuticals Ltd (GLMD) is expected to reach an average price of $20.42 in 2035, with a high prediction of $23.19 and a low estimate of $20.48. This indicates an $639.91% rise from the last recorded price of $2.76.
- Galmed Pharmaceuticals Ltd (GLMD) stock is projected to chart a bullish course in 2040, with an average price target of $62.83, representing an $2,176% surge from its current level. The forecast ranges from a conservative $62.98 to a sky-high $64.07.
- Our analysts predict Galmed Pharmaceuticals Ltd (GLMD) to jump 4,609% by 2045, soaring from $132.53 to an average price of $129.98, potentially reaching $134.11. While $132.53 is the low estimate, the potential upside is significant.
- Galmed Pharmaceuticals Ltd (GLMD) stock is expected to climb by 2050, reaching an average of $206.72, a $7,390% jump from its current level. However, a wide range of estimates exists, with high and low targets of $212.37 and $212.27, respectively, highlighting the market's uncertainty.
Galmed Pharmaceuticals Ltd Stock (GLMD) Year by Year Forecast
Galmed Pharmaceuticals Ltd Stock (GLMD) Price Forecast for 2025
Galmed Pharmaceuticals Ltd Stock (GLMD) is expected to reach an average price of $17.59 in 2025, with a high prediction of $34.47 and a low estimate of $0.6993. This indicates an +537.16% rise from the last recorded price of $2.76.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| February, 2025 | $12.99 | $0.6993 | $15.94 | +370.56% |
| March, 2025 | $17.19 | $2.9644 | $6.686 | +522.69% |
| April, 2025 | $35.58 | $17.20 | $33.18 | +1,189% |
| May, 2025 | $10.90 | $14.50 | $34.47 | +295.01% |
| June, 2025 | $7.8261 | $19.23 | $16.34 | +183.56% |
| July, 2025 | $1.5434 | $11.41 | $9.0304 | -44.08% |
| August, 2025 | $12.87 | $8.9868 | $7.5237 | +366.20% |
| September, 2025 | $9.7909 | $12.34 | $13.74 | +254.74% |
| October, 2025 | $14.01 | $5.0647 | $7.9344 | +407.54% |
| November, 2025 | $23.38 | $19.30 | $20.38 | +747.17% |
| December, 2025 | $27.90 | $23.63 | $25.05 | +910.84% |
Galmed Pharmaceuticals Ltd Stock (GLMD) Price Forecast for 2026
The predicted value for Galmed Pharmaceuticals Ltd (GLMD) in 2026 is set at an average of $14.85. Estimates vary from a peak of $24.91 to a trough of $4.7943, indicating an +438.04% surge from the present price of $2.76.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $10.57 | $17.98 | $22.44 | +283.08% |
| February, 2026 | $21.60 | $15.77 | $14.90 | +682.49% |
| March, 2026 | $16.42 | $20.32 | $18.49 | +494.95% |
| April, 2026 | $1.2877 | $4.7943 | $24.91 | -53.34% |
| May, 2026 | $8.2615 | $10.98 | $12.07 | +199.33% |
| June, 2026 | $15.09 | $16.04 | $13.25 | +446.57% |
| July, 2026 | $28.38 | $16.42 | $21.85 | +928.17% |
| August, 2026 | $11.58 | $15.93 | $23.00 | +319.43% |
| September, 2026 | $17.14 | $15.25 | $13.86 | +521.14% |
| October, 2026 | $13.77 | $20.16 | $19.52 | +398.81% |
| November, 2026 | $8.7411 | $10.39 | $14.25 | +216.71% |
| December, 2026 | $14.46 | $11.68 | $9.8648 | +423.85% |
Galmed Pharmaceuticals Ltd Stock (GLMD) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Galmed Pharmaceuticals Ltd (GLMD) is $22.35, with a high forecast of $33.93 and a low forecast of $10.76. This indicates an +709.66% increase from the last price of $2.76.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $14.08 | $14.08 | $14.10 | +410.22% |
| February, 2027 | $12.36 | $10.76 | $13.59 | +347.68% |
| March, 2027 | $20.17 | $15.54 | $17.32 | +630.91% |
| April, 2027 | $25.95 | $21.62 | $23.85 | +840.10% |
| May, 2027 | $23.77 | $25.27 | $25.38 | +761.25% |
| June, 2027 | $26.64 | $24.15 | $23.99 | +865.14% |
| July, 2027 | $21.46 | $23.26 | $24.48 | +677.60% |
| August, 2027 | $20.64 | $20.66 | $19.74 | +647.66% |
| September, 2027 | $34.45 | $23.43 | $33.02 | +1,148% |
| October, 2027 | $34.07 | $33.52 | $33.93 | +1,134% |
| November, 2027 | $30.18 | $30.83 | $32.82 | +993.36% |
| December, 2027 | $31.32 | $30.13 | $30.42 | +1,035% |
Galmed Pharmaceuticals Ltd Stock (GLMD) Price Forecast for 2028
In 2028, Galmed Pharmaceuticals Ltd (GLMD) is projected to reach an average price of $22.85, with a high projection of $29.91 and a low estimate of $15.80. This indicates an +728.02% rise from the last price of $2.76.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $29.29 | $29.65 | $29.91 | +961.28% |
| February, 2028 | $29.95 | $29.53 | $29.52 | +985.10% |
| March, 2028 | $27.13 | $27.13 | $27.28 | +883.00% |
| April, 2028 | $26.91 | $26.91 | $26.66 | +874.85% |
| May, 2028 | $21.55 | $25.27 | $26.12 | +680.91% |
| June, 2028 | $16.93 | $17.81 | $20.47 | +513.31% |
| July, 2028 | $17.02 | $17.77 | $17.13 | +516.69% |
| August, 2028 | $18.09 | $17.71 | $17.54 | +555.36% |
| September, 2028 | $18.46 | $18.06 | $17.41 | +568.90% |
| October, 2028 | $16.01 | $17.79 | $17.66 | +480.16% |
| November, 2028 | $15.61 | $15.84 | $16.02 | +465.68% |
| December, 2028 | $15.94 | $15.80 | $15.48 | +477.41% |
Galmed Pharmaceuticals Ltd Stock (GLMD) Price Forecast for 2029
The 2029 price forecast for Galmed Pharmaceuticals Ltd Stock (GLMD) is $44.67 on average, with a high prediction of $88.93 and a low estimate of $0.407. This represents an +1,518% increase from the previous price of $2.76.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $15.99 | $15.99 | $16.36 | +479.48% |
| February, 2029 | $14.95 | $14.97 | $15.64 | +441.51% |
| March, 2029 | $13.55 | $13.55 | $14.54 | +390.99% |
| April, 2029 | $12.46 | $12.46 | $13.18 | +351.27% |
| May, 2029 | $10.70 | $10.72 | $12.05 | +287.81% |
| June, 2029 | $9.2897 | $9.314 | $10.31 | +236.58% |
| July, 2029 | $7.7749 | $7.8348 | $8.8323 | +181.70% |
| August, 2029 | $6.0722 | $6.096 | $7.4183 | +120.01% |
| September, 2029 | $4.6583 | $4.6809 | $5.6307 | +68.78% |
| October, 2029 | $2.9271 | $2.9381 | $4.252 | +6.06% |
| November, 2029 | $1.4391 | $1.4818 | $2.5326 | -47.86% |
| December, 2029 | $104.83 | $0.407 | $88.93 | +3,698% |
Galmed Pharmaceuticals Ltd Stock (GLMD) Price Forecast for 2030
Galmed Pharmaceuticals Ltd Stock (GLMD) is expected to reach an average price of $111.50 in 2030, with a high forecast of $132.75 and a low forecast of $90.25. This signifies an +3,940% surge from the last price of $2.76.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $114.01 | $112.21 | $111.91 | +4,031% |
| February, 2030 | $101.41 | $103.32 | $106.76 | +3,574% |
| March, 2030 | $114.91 | $109.84 | $111.61 | +4,063% |
| April, 2030 | $119.55 | $119.82 | $115.88 | +4,232% |
| May, 2030 | $123.66 | $123.94 | $121.84 | +4,380% |
| June, 2030 | $134.21 | $134.21 | $132.75 | +4,763% |
| July, 2030 | $118.87 | $123.07 | $126.07 | +4,207% |
| August, 2030 | $98.92 | $99.18 | $117.11 | +3,484% |
| September, 2030 | $87.21 | $96.21 | $95.95 | +3,060% |
| October, 2030 | $91.90 | $90.25 | $91.50 | +3,230% |
| November, 2030 | $123.25 | $92.13 | $102.10 | +4,365% |
| December, 2030 | $125.34 | $123.96 | $121.14 | +4,441% |
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):